Analyst Price Targets — MRVI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 12:53 pm | — | Deutsche Bank | $6.00 | $4.50 | TheFly | Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank |
| December 15, 2025 11:28 am | Brandon Couillard | Wells Fargo | $4.50 | $3.61 | TheFly | Maravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo |
| March 21, 2025 2:28 pm | — | Stifel Nicolaus | $5.00 | $2.27 | TheFly | Maravai Lifesciences price target lowered to $5 from $10 at Stifel |
| May 9, 2024 6:15 am | Catherine Schulte | Robert W. Baird | $10.00 | $8.87 | TheFly | Maravai Lifesciences price target raised to $10 from $8 at Baird |
| December 14, 2022 8:30 am | — | Deutsche Bank | $25.00 | $15.03 | Benzinga | Deutsche Bank Initiates Coverage On Maravai LifeSciences with Buy Rating, Announces Price Target of $25 |
| December 7, 2022 4:42 am | — | RBC Capital | $22.00 | $12.50 | Benzinga | RBC Capital Initiates Coverage On Maravai LifeSciences with Outperform Rating, Announces Price Target of $22 |
Latest News for MRVI
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen…
Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares. Key Headlines Impacting Maravai LifeSciences Here are the key news stories impacting
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences (NASDAQ: MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRVI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.